Last August, the FDA approved CAR-T therapy for the treatment of acute lymphoblastic leukemia (ALL). A year later, scientists at the University of Texas MD Anderson Cancer Center, in conjunction with the Pediatric Acute Lung Injury and Sepsis Researcher Network (PALISI), published a comprehensive consensus guide on children receiving CAR-T cell therapy. The guide brings together the lessons learned by top experts in identifying early signs and symptoms of treatment-related toxicity and details
...
Más informaciones
how to respond to these symptoms.
CAR-T therapy is a genetic modification of a specific protein (chimeric antigen receptor, CAR) into a T cell after extraction of a patient's T cells. After reinjection of the modified T cells into the human body, the antigen (CD19) on the surface of leukemia cells can be specifically identified and killed. The data showed that the success rate of ALL patients after CAR-T clinical cell immunotherapy reached 90%. The ongoing research is aimed at expanding the use of this therapy in other cancers.
https://www.creative-biolabs.com/car-t/cellrapeutics-chimeric-antigen-receptor-car-technology.htm
